

**Virginia Medicaid
Pharmacy & Therapeutics Committee Meeting
Agenda**

Thursday, March 18, 2021 – 11 AM

**This is an electronic public meeting held pursuant to
Items 4-0.01(g) in House Bill 29 and House Bill 30.**

The FOIA Councils “*Electronic Meetings Public Comment*” form
for submitting feedback on this electronic meeting may be accessed at
<http://foiacouncil.dls.virginia.gov/sample%20letters/welcome.htm>

+1-517-466-2023 US Toll
+1-866-692-4530 US Toll Free
Event number (access code): 185 813 0835
Event password: Meeting1

[Click Here to Enter the Event](#)

Welcome and Comments

Karen Kimsey, Agency Director

Call to Order

Chethan Bachireddy, MD, CMO, Chair

Drug Utilization Review (DUR) Board Report

Rachel Cain, PharmD

**Approval of Minutes from September 17, 2020 Meeting
(vote)**

P&T Committee Members

PDL Management

P&T Committee Members

PDL Phase I – New Drug Review (*Therapeutic Class*)

Brand Drugs

- Alkindi Sprinkle® and Ortikos™ (Glucocorticoids, Oral)
- Impeklo® (Steroids, Topical Very High Potency)

(vote)

Generics Drugs or New Dosage Forms

- Rufinamide new generic for Banzel Suspension (Anticonvulsants)
- Azelastine/Fluticasone Nasal Spray New generic for Dymista (Intranasal Rhinitis Agents)
- Gemfibrozil new generic for Lopid & icosapent ethyl new generic for Vascepa (Lipotropics, Other)

(vote)

PDL Phase II – Annual Review: Classes with updates

Analgesics

- Antimigraine Agents
- Antimigraine Agents Other
- Non-Steroidal Anti-Inflammatory Drugs (NSAID) (includes Cox-2 inhibitors and topical agents)
- Opioid Dependency Treatment Agents (**Closed Class**) (includes oral buprenorphine)
- Opioids: Long Acting
- Opioids: Short Acting (includes combination drugs and lozenges)

(vote)

Antibiotics / Anti-Infectives

- Gastrointestinal
- Ketolides & Macrolides (Adult and Pediatric)
- Quinolones (Otic)

(vote)

Antivirals

- Antivirals for Influenza

Blood Modifiers

- Antihyperuricemics

Cardiac

- Anticoagulants (*includes oral agents, low molecular weight heparins & Factor XA Inhibitors*) (Closed Class)
(vote)

Central Nervous System

- Antihyperkinesis/CNS Stimulants (Closed Class)
- Multiple Sclerosis Agents
- Neuropathic Pain
- Smoking Cessation Agents

(vote)

Dermatologic Agents (Topical)

- Antifungal Agents, Topical

Endocrine and Metabolic Agents

- Bone Resorption Suppression and Related Agents (includes bisphosphonates, calcitonins and others)
- Hypoglycemics: Incretin- mimetics- Exenatide (includes DPPIV & combination) (Closed Class)
- Hypoglycemics: Insulins
- Hypoglycemics: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor (Closed class)

(vote)

Immunological Agents

- Self-administered Cytokine & CAM Antagonists with Related Agents including Methotrexate (*all indications: Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Ankylosing Spondylitis (AS), Plaque Psoriasis, Psoriatic Arthritis (PsA), Crohn's Disease (CD), Ulcerative Colitis, Cryopyrin-Associated Periodic Syndromes (CAPS)*) (Closed class)

(vote)

Classes with no significant clinical change

Antibiotics / Anti-Infectives

- Antibiotics (topical)
- Antifungals (oral)
- Cephalosporins (Second and Third Generations)
- Quinolones (Second and Third Generations)

Antivirals

- Antivirals for Herpes (HSV)

Blood Modifiers

- Erythropoiesis Stimulating Proteins

Cardiac

- Platelet Aggregation Inhibitors

Central Nervous System

- Alzheimer's Agents (Cholinesterase Inhibitors & NMDA Receptor Antagonist) name updated 12/2020
- Skeletal Muscle Relaxants

Contraceptives no change

- Long-Acting Reversible Contraceptives (LARCS) (includes long-acting IUDs & injectable)

Dermatologic Agents (Topical)

- Acne Agents (includes benzoyl peroxide, clindamycin, retinoids & combinations)

- Antivirals, Topical
- Psoriasis Agents
- Rosacea Agents

Endocrine and Metabolic Agents

- Androgenic Agents
- Estrogens (vaginal)
- Hypoglycemics: Alpha-Glucosidase Inhibitors
- Hypoglycemics: Meglitinides
- Hypoglycemics: Metformin
- Hypoglycemics: Sulfonylureas
- Hypoglycemics: Thiazolidinediones
- Pancreatic Enzymes
- Progestational Agents

Immunological Agents

- Methotrexate

(vote)

Confidential Meeting (Pricing Information Discussion)

(vote)

P&T Committee Members & DMAS Staff

Criteria Discussion of Phase I New Drugs

Or criteria changes

Criteria Discussion of Phase II Drugs

(vote)

P&T Committee Members

P&T Committee Members

**Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.*

Next Meeting – September 16, 2021 (tentative)

Chair